InMed Pharmaceuticals Inc.
IN.TO
Toronto Stock Exchange4.19
CAD
-0.07
- -
InMed Pharmaceuticals Inc.
IN.TO
(Toronto Stock Exchange)
Recent
price
4.19
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- InMed Pharmaceuticals Inc. InMed Pharmaceuticals Inc. (NASDAQ: INM; TSX: IN) is a clinical-stage biopharmaceutical company focused on developing proprietary small molecule drug candidates targeting CB1/CB2 receptors for diseases with high unmet medical needs, including Alzheimer's disease, dry age-related macular degeneration, and epidermolysis bullosa; its pipeline features INM-901, which demonstrates neuroprotective effects, neurite outgrowth, and reduction in neuroinflammation in preclinical Alzheimer's models; INM-089, a selective dual CB1/CB2 agonist providing neuroprotection of photoreceptors and functional improvements in dry AMD preclinical studies; and INM-755, a cannabinol-based topical cream that completed Phase 2 clinical trials for epidermolysis bullosa. Through its subsidiary BayMedica, the company manufactures and commercializes high-purity, bioidentical rare cannabinoids such as cannabichromene (CBC), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), and cannabicitran (CBTC) for the health and wellness industry, employing proprietary biosynthesis technologies like IntegraSyn to produce pharmaceutical-grade cannabinoids free of THC. Founded in 1981 and headquartered in Vancouver, British Columbia, Canada, with additional operations in the United States including Nevada and California facilities, InMed serves global markets through contract manufacturing organizations in the US and Europe. Recent developments include the appointment of industry veterans John Bathery and Neil Klompas to its Board of Directors in October 2025; presentation of new INM-901 preclinical data showing significant reductions in pro-inflammatory cytokines and inflammasome markers at the Alzheimer's Association International Conference in July 2025; a private placement closing in June 2025 raising funds via 1,952,363 common shares and options; advancements in INM-089 intravitreal formulation announced in February 2025; granting of patents for novel compounds and filing of additional INM-901 patent applications in 2024-2025; entry into a standby equity purchase agreement in December 2024; and a share consolidation in November 2024 to meet Nasdaq listing requirements following a hearings panel exception.